« Return to News | Awards & Advancement

Tengion adds renal experts to R&D advisory panel

Tuesday, March 29, 2011 12:19 PM

Tengion, a company involved in regenerative medicine, announced the addition of two renal research and clinical experts, Ben Humphreys, M.D., Ph.D., from the Harvard Stem Cell Institute and Giuseppe Remuzzi, M.D., F.R.C.P., from the Mario Negri Institute, to its panel of R&D advisors.

Remuzzi is the head of nephrology and dialysis and chairman of the department of transplantation at Bergamo Hospital and head of the Negri Bergamo Laboratories. He leads a team of researchers studying human renal diseases and their corresponding experimental models from the perspective of pathophysiology and therapeutic intervention.

Humphreys is an assistant professor of medicine at Harvard Medical School and principal faculty member of the Harvard Stem Cell Institute, where he is also co-director of the Institute’s Kidney Program. He is the recipient of a Harvard Stem Cell Institute Seed Grant, the National Kidney Foundation Young Investigator Award and the American Society of Nephrology Gottschalk Research Scholar Award. He investigates kidney repair for translation into therapies for kidney disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.